About: New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 08 December 2008

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) article scientifique publié en 2008 (fr) наукова стаття, опублікована в грудні 2008 (uk) artículu científicu espublizáu n'avientu de 2008 (ast) scientific article published on 08 December 2008 (en)
publication date	wds:Q82877410-838638B8-A7F8-4BBB-BB1F-591429C275DB
publication date	2008-12-08 00:00:00Z (xsd:dateTime)
cites work	wds:Q82877410-3123DA9C-D66E-4B01-B1B6-855814683250
cites work	Statistical problems in the reporting of clinical trials. A survey of three medical journals.
author name string	wds:Q82877410-1CC72916-81F5-4F17-A0C8-DAAE995EAE84 wds:Q82877410-1D374B1E-B0DA-40AF-8CE3-2982440AB29B wds:Q82877410-BAF86758-188D-4557-BE24-56BF3188CBFD wds:Q82877410-D2D0A6BE-314B-479C-B18A-48E6EA12E319 wds:Q82877410-DB8A0263-11A5-4907-B269-A364265EB75A wds:Q82877410-FB85D67E-CF79-42E4-9966-A225BB65A3F5 wds:Q82877410-FBEE50C1-E0F2-4D79-A925-DA28A434B331
author name string	Stephen L Chan Philip J Johnson Edwin P Hui Frankie K F Mo Anthony T C Chan Kwok C Lam Wing M Ho
rdfs:label	New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy (en) New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy (nl)
skos:prefLabel	New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy (en) New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy (nl)
name	New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy (en) New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy (nl)
author	wds:Q82877410-5B1CACBA-37C6-49CD-A59D-CC3076D53935 wds:Q82877410-605DE4F0-0D13-40C6-9EE8-91CF2D4647DC wds:Q82877410-E619A42F-3318-4006-A71C-932D3752422B
author	Tony Mok Winnie Yeo Brigette Ma
title	wds:Q82877410-EC88BB4C-78CB-4CBB-BC9A-01F45073B177
title	New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy (en)
page(s)	wds:Q82877410-DA9EADD0-FEE1-4E23-92BE-082B9EA76BC9
page(s)	446-452
instance of	wds:Q82877410-FD718C24-EDC9-48E7-B9DA-A0874A11D0D5
instance of	scholarly article
main subject	wds:Q82877410-28921BDF-4788-4F16-A11E-1FD7DD2DEDBD
main subject	hepatocellular carcinoma
PubMed ID	wds:Q82877410-1349D95A-CF7E-450A-BB7C-0BBBE267CC18
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/19064965
PubMed ID	19064965
published in	wds:Q82877410-C63E0B23-0E74-4F74-B0A8-33F053D42011
published in	Journal of Clinical Oncology
issue	wds:Q82877410-9A7C76B9-EA33-4E20-834D-72EA465B704F
volume	wds:Q82877410-FF8A1DE2-60AD-4B19-82F3-5628F6FA9D6F
issue	3
volume	27
DOI	wds:Q82877410-04145FF8-921B-4C29-A75B-A2D547DC16A6
DOI	http://dx.doi.org/10.1200/JCO.2008.18.8151
DOI	10.1200/JCO.2008.18.8151
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q82877410
is cites work of	Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma Research reporting standards for radioembolization of hepatic malignancies. Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma. Sorafenib in advanced hepatocellular carcinoma: a nationwide retrospective study of efficacy and tolerability. Circulating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection Correlation analysis of preoperative serum alpha-fetoprotein (AFP) level and prognosis of hepatocellular carcinoma (HCC) after hepatectomy Global gene profiling of spontaneous hepatocellular carcinoma in B6C3F1 mice: similarities in the molecular landscape with human liver cancer Sorafenib: where do we go from here? Predictive biomarkers of sorafenib efficacy in advanced hepatocellular carcinoma: Are we getting there? The significance of early alpha-fetoprotein level changes in predicting clinical and survival benefits in advanced hepatocellular carcinoma patients receiving sorafenib Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma Treatment of advanced hepatocellular carcinoma with very low levels of amplitude-modulated electromagnetic fields. Drug development for hepatocellular carcinoma: knowing the past helps to understand the future Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). Phase 2 trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma Evaluation of antiangiogenic efficacy in advanced hepatocellular carcinoma: Biomarkers and functional imaging The present and the future landscape of treatment of advanced hepatocellular carcinoma. Phase I/II study of temsirolimus for patients with unresectable Hepatocellular Carcinoma (HCC)- a correlative study to explore potential biomarkers for response Highlights for α-fetoprotein in determining prognosis and treatment monitoring for hepatocellular carcinoma Alpha-fetoprotein response correlates with EASL response and survival in solitary hepatocellular carcinoma treated with transarterial therapies: a subgroup analysis Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus statement A new therapeutic assessment score for advanced hepatocellular carcinoma patients receiving hepatic arterial infusion chemotherapy Long-term clinical outcomes of hepatic arterial infusion chemotherapy with cisplatin with or without 5-fluorouracil in locally advanced hepatocellular carcinoma. The Prognostic Value of Alpha-Fetoprotein Response for Advanced-Stage Hepatocellular Carcinoma Treated with Sorafenib Combined with Transarterial Chemoembolization Elevated serum alpha fetoprotein levels promote pathological progression of hepatocellular carcinoma Management of hepatocellular carcinoma: beyond sorafenib. Telomerase inhibition decreases alpha-fetoprotein expression and secretion by hepatocellular carcinoma cell lines: in vitro and in vivo study Alpha-fetoprotein activates AKT/mTOR signaling to promote CXCR4 expression and migration of hepatoma cells Hepatic Resection Improved the Long-Term Survival of Patients with BCLC Stage B Hepatocellular Carcinoma in Asia: a Systematic Review and Meta-Analysis Albumin-to-alkaline phosphatase ratio: a novel prognostic index for hepatocellular carcinoma Alpha-1-fucosidase as a prognostic indicator for hepatocellular carcinoma following hepatectomy: a large-scale, long-term study Update on biomarkers of hepatocellular carcinoma Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study Impact of preoperative α-fetoprotein level on disease-free survival after liver transplantation for hepatocellular carcinoma. Development of systemic therapy for hepatocellular carcinoma at 2013: updates and insights. Early α-fetoprotein response predicts survival in patients with advanced hepatocellular carcinoma treated with sorafenib Transarterial radioembolization for hepatocellular carcinoma: a review Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma with Portal Vein Thrombosis: Impact of Early Response to 4 Weeks of Treatment Organic Cation Transporter 1 (OCT1) mRNA expression in hepatocellular carcinoma as a biomarker for sorafenib treatment Assessment of treatment outcomes based on tumor marker trends in patients with recurrent hepatocellular carcinoma undergoing trans-catheter arterial chemo-embolization. Prognostic value of α-fetoprotein and des-γ-carboxy prothrombin responses in patients with hepatocellular carcinoma treated with transarterial chemoembolization.

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 172 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software